Prakt. lékáren. 2008; 4(6): 282-285

PHARMACOTHERAPY OF INFLAMMATORY RHEUMATIC DISEASE

MUDr. Radka Svobodová
Revmatologický ústav, Praha

The paper aims to briefly and clearly describe the treatment options for inflammatory rheumatic diseases and to highlight the most common adverse drug effects.

Currently, both the so-called disease-modifying drugs and biological drugs are used to treat these conditions. However, nonsteroidal antirheumatics, analgesics, and glucocorticoids are also an integral part of pharmacotherapy. Due to frequent multimorbidity in patients, it is not always easy to prescribe a proper combination of drugs which, in a particular patient, would be the most beneficial.

Keywords: Key words: inflammatory rheumatic diseases, systemic connective tissue diseases, extra-articular manifestations, disease-modifying drugs, adverse drug effects.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svobodová R. PHARMACOTHERAPY OF INFLAMMATORY RHEUMATIC DISEASE. Praktické lékárenství. 2008;4(6):282-285.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. American College of Rheumatology Ad Hoc Committe on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 723-731. Go to original source...
    2. Braun J, Kästner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2008; Jan 58: 73-81. Go to original source... Go to PubMed...
    3. Buchanan NMM, Toubi E, Khamasta MA, et al. Hydroxychloroquine and lupus pregnancy review of a series of 36 cases. Ann Rheum Dis 1996; 55: 486-488. Go to original source... Go to PubMed...
    4. Combe B, Landewe R, Lukas C, et al. Eular recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 34-45. Go to original source... Go to PubMed...
    5. Dijkmans BAC, De Vries E, De Vreede. Synergistic and additive effects of disease modifying antirheumatic drugs combined with chloroquine on the mitogen-drive stimulation of mononuclear cells. Clin Exp Rheumatol 1990; 8: 455-459. Go to PubMed...
    6. Dixon ASTJ, Elmery P. Local injection therapy in rheumatic diseases. Eular Publishers 1992, 4th ed.; 9-11.
    7. Donnenfeld AE, Pastiszak A, Noah JS, et al. Methotrexate exposure prior and during pregnancy. Teratology 1994; 49: 79-81. Go to original source... Go to PubMed...
    8. Doria A, Ponticelli C, Mosca M, et al. A randomized trial comparing cyclosporine versus azathioprine for maintenance therapy in difuse lupus nephritis. Abstrakt book 7th Internation Congress on SLE New York 2004; 9-13: W47A.
    9. Felson D, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1449-1461. Go to original source... Go to PubMed...
    10. Felson DT, Anderson JJ, Meenan RF, et al. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992; 35: 1117-1125. Go to original source... Go to PubMed...
    11. Griffiths B, Emery P. The treatment of lupus with cyclosporin A. Lupus 2001; 10: 16. Go to original source... Go to PubMed...
    12. Janssen NM, Genta MS. The effects of immunosuppresive and anti-inflammatory medications on fertility, pregnancy and lactation. Arch Intern Med 2000; 160: 610-619. Go to original source... Go to PubMed...
    13. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double. blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50: 1939-1950. Go to original source... Go to PubMed...
    14. Kremer JM. The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol 1997; 21: 1-5.
    15. Kremer JM, Genovese M, Caldwell J, et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 2004; 31: 1521-1531. Go to PubMed...
    16. Landewe RBM, Boers M, Verhoven AC, et al. COBRA Combination therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2002; 46: 347-356. Go to original source... Go to PubMed...
    17. Landewe RBM, Goei HS, Rijthoven AWAM, et al. Cyclosporine in common clinical practise: An estimation of the benefit/risk ratio in patients with rheumatoid arthritis. J Rheumatol 1994; 21: 1631-1636. Go to PubMed...
    18. Lipsky PL, Abramson SB, Crofford L, et al. The classification of cyclooxygenase inhibitors. J Rheumatol 1998; 25: 2298-2302. Go to PubMed...
    19. Neson JL, Ostensen M. Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 1997; 23: 195-212. Go to original source... Go to PubMed...
    20. Parke A, West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996; 23: 1715-1718. Go to PubMed...
    21. Saag KG. Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence. Am J Med 1997; 103: 31S-39S. Go to original source... Go to PubMed...
    22. Schnabel A, et al. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998; 41: 1215-1220. Go to original source...
    23. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity of drugs for osteoartrhritis and rheumatoid arthritis. The CLASS study: a randomised, controlled trial J Am Med Assoc 2000; 284: 1247-1249. Go to original source... Go to PubMed...
    24. Skosey JL. Comparison of responses to and adverse effects of graded doses of sulphasalazine in the treatment of rheumatoid arthritis. J Rheumatol 1988; 15 (Suppl 16): 5-8.
    25. Spadaro A, Riccieri V, Silli-Scavalli A, et al. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995; 13: 589-593. Go to PubMed...
    26. Takken T, Van der Net J, Helders PJM. Methotrexate for treating juvenile idiopathic arthritis (Cochrane Database of Systemic Reviews). In: The Cochrane Library, Issue 4, 2001. Oxford: Update Software.
    27. Vencovský J, Jarošová K, Macháček S, et al. Cyclosporine A versus methotrexat in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 200; 29: 95-102.
    28. Walz-Leblanc BAE, Dagenais P, Urowitz MB, et al. Methotrexate in SLE. J Rheumatol 1994; 21: 836-838. Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.